Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Capital Expenditures (2016 - 2025)

Lineage Cell Therapeutics (LCTX) has 16 years of Capital Expenditures data on record, last reported at $399000.0 in Q4 2025.

  • For Q4 2025, Capital Expenditures fell 27.98% year-over-year to $399000.0; the TTM value through Dec 2025 reached $522000.0, down 7.61%, while the annual FY2025 figure was $522000.0, 7.61% down from the prior year.
  • Capital Expenditures reached $399000.0 in Q4 2025 per LCTX's latest filing, up from $122000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $554000.0 in Q4 2024 and bottomed at -$401000.0 in Q4 2022.
  • Average Capital Expenditures over 5 years is $105882.4, with a median of $97000.0 recorded in 2022.
  • Peak YoY movement for Capital Expenditures: skyrocketed 508.79% in 2024, then plummeted 292.0% in 2025.
  • A 5-year view of Capital Expenditures shows it stood at $11000.0 in 2021, then crashed by 3745.45% to -$401000.0 in 2022, then skyrocketed by 122.69% to $91000.0 in 2023, then surged by 508.79% to $554000.0 in 2024, then decreased by 27.98% to $399000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Capital Expenditures were $399000.0 in Q4 2025, $122000.0 in Q3 2025, and -$96000.0 in Q2 2025.